Can’t Stop Buying This Dividend Juggernaut: ABBV Growth
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
A long-time investor explains why AbbVie’s mix of rapidly growing immunology drugs and a dependable dividend keeps dr...
Bitcoin’s network activity is rising toward multi-year highs even as BTC trades beneath its all-time high, fueled by ...
Meta is pursuing prediction markets, signaling a major shift away from its metaverse push. The move could reshape its...
Gen X is turning to facelifts as GLP-1 weight-loss drugs reshape faces, pushing middle-aged adults to consider surgic...
A Manhattan federal judge sentenced a New York City teenager to 66 months in prison after he admitted to igniting a f...
A social-media frenzy around trillionaire wealth centers on Elon Musk, sparking a debate about how market values, pri...
World Cup 2026 in the U.S. has sparked a spending spree among fans who travel with dreams of the tournament, even if ...
A Microsoft Copilot AI forecast places Solana on a volatile path to 2026, with a base bull range of $250-$400 and a p...
Late-career workers who enroll in Medicare while still employed and continue HSA deposits risk a 6% annual excise tax...
An Oppenheimer analyst has floated a $10 trillion valuation for SpaceX within five years, anchored by Starlink's cash...
Retail investors sold NVIDIA, Microsoft, and Oracle to fund SpaceX private rounds, signaling a major shift in how eve...
Micron’s stock sprinted higher on AI-driven demand, prompting a strategist to flag a potential entry on a pullback. T...